Insider Selling: Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) CFO Sells 2,100 Shares of Stock

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) CFO Thomas Patrick Kelly sold 2,100 shares of the business’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $25.20, for a total value of $52,920.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Thomas Patrick Kelly also recently made the following trade(s):

  • On Wednesday, June 19th, Thomas Patrick Kelly sold 177 shares of Deciphera Pharmaceuticals stock. The shares were sold at an average price of $25.00, for a total value of $4,425.00.
  • On Wednesday, May 22nd, Thomas Patrick Kelly sold 1,473 shares of Deciphera Pharmaceuticals stock. The shares were sold at an average price of $25.06, for a total value of $36,913.38.
  • On Wednesday, May 1st, Thomas Patrick Kelly sold 13,500 shares of Deciphera Pharmaceuticals stock. The shares were sold at an average price of $22.93, for a total value of $309,555.00.

Shares of NASDAQ:DCPH traded down $0.79 during mid-day trading on Friday, reaching $22.55. The stock had a trading volume of 435,085 shares, compared to its average volume of 204,563. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.55 and a current ratio of 9.55. The firm has a market cap of $892.10 million, a P/E ratio of -8.00 and a beta of 2.67. Deciphera Pharmaceuticals Inc has a 1 year low of $18.55 and a 1 year high of $43.92. The business has a 50 day moving average of $23.32.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its earnings results on Thursday, May 9th. The company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.41). As a group, equities research analysts anticipate that Deciphera Pharmaceuticals Inc will post -4.57 EPS for the current year.

Several large investors have recently bought and sold shares of the stock. Rhumbline Advisers increased its stake in Deciphera Pharmaceuticals by 53.6% during the fourth quarter. Rhumbline Advisers now owns 11,466 shares of the company’s stock worth $241,000 after acquiring an additional 4,000 shares during the last quarter. Eversept Partners LP bought a new stake in Deciphera Pharmaceuticals during the fourth quarter worth approximately $1,463,000. Dimensional Fund Advisors LP bought a new stake in Deciphera Pharmaceuticals during the fourth quarter worth approximately $4,337,000. Legal & General Group Plc increased its stake in Deciphera Pharmaceuticals by 55.4% during the third quarter. Legal & General Group Plc now owns 1,647 shares of the company’s stock worth $64,000 after acquiring an additional 587 shares during the last quarter. Finally, BlackRock Inc. increased its stake in Deciphera Pharmaceuticals by 73.6% during the fourth quarter. BlackRock Inc. now owns 1,173,245 shares of the company’s stock worth $24,625,000 after acquiring an additional 497,427 shares during the last quarter. Institutional investors own 58.89% of the company’s stock.

Several brokerages have recently commented on DCPH. Canaccord Genuity lowered their price objective on Deciphera Pharmaceuticals from $55.00 to $50.00 and set a “buy” rating on the stock in a research report on Friday, March 15th. BidaskClub upgraded Deciphera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, April 24th. ValuEngine upgraded Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, April 1st. Finally, Piper Jaffray Companies boosted their target price on Deciphera Pharmaceuticals from $50.00 to $55.00 and gave the stock an “overweight” rating in a research report on Monday, June 3rd. They noted that the move was a valuation call. Two analysts have rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $40.86.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.

Recommended Story: What is a stock split?

Insider Buying and Selling by Quarter for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.